GW273297X
GW273297X is a selective CYP27A1 inhibitor. GW273297X blocks 27-hydroxycholesterol biosynthesis and sterol product formation in human macrophages. GW273297X reduces cancer cells colonization by inhibiting pro-metastatic effects of 27-hydroxycholesterol. GW273297X can be used for the researches of cancer and metabolic disease, such as breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 1713317-28-2
- Formula: C29H48O3
- Molecular Weight:444.69
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CYP27A1 |
GW273297X (1 μM; 24 h) potently inhibits CYP27A1 enzyme activity in PMA-differentiated THP-1 human macrophage-like cells[2].
GW273297X (1 μM; 24 h) potently inhibits CYP27A1 enzyme activity in PMA (HY-18739)-differentiated THP-1 human macrophage-like cells when cholesterol is used as substrate[2].
GW273297X (1 μM; 24 h) potently and nearly completely inhibits CYP27A1 enzyme activity in primary human monocyte-derived macrophages (HMDMs)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GW273297X (100 mg/kg; s.c.; daily; 5 days) reduces early-stage lung metastatic colonization by Met1 and E0771 breast cancer cells in naive wild-type mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized APOE3 with E0771-iRFP cells (ovariectomized female, ~6 weeks of age at ovariectomy)[1]
-
Dosage:100 mg/kg
-
Administration:s.c.; daily; 28 days
-
Result:Attenuated the increased lung metastatic burden induced by the high-fat diet, as measured by relative fluorescence of iRFP-expressing tumor cells.
-
Animal Model:wild-type with Met1 and E0771 breast cancer cells (naive)[1]
-
Dosage:100 mg/kg
-
Administration:s.c.; daily; 5 days
-
Result:Reduced the number of Met1 metastatic colonies in the lungs, as measured by relative fluorescence of iRFP-expressing tumor cells.
Reduced lung metastatic colonization by E0771 cells; this effect was reversed by co-pretreatment with exogenous 27-hydroxycholesterol.
Chemical Information
-
CAS No. 1713317-28-2
-
Molecular Weight 444.69
-
Formula C29H48O3
-
SMILES
C[C@@]12[C@]3([H])[C@]([C@@H](C[C@]1([H])CC(OC)(CC2)OC)O)([H])[C@@]4([H])[C@](CC3)([C@H](CC4)[C@H](C)CCCCC#C)C
-
Synonyms
G297X
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Baek AE, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8(1):864. Published 2017 Oct 11. [Content Brief]
[2]. Quinn CM, et al. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARgamma ligands. Biochem J. 2005;385(Pt 3):823-830. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GW273297X Related Classifications
HY-176497 Related Classifications
Powered by Bioz